Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Research highlights from the 2018 ERS International Congress: interstitial lung diseases.
Alfaro TM, Moor CC, Alfieri V, Jeny F, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, Antoniou K, Poletti V. Alfaro TM, et al. Among authors: kreuter m. ERJ Open Res. 2019 Feb 18;5(1):00215-2018. doi: 10.1183/23120541.00215-2018. eCollection 2019 Feb. ERJ Open Res. 2019. PMID: 30792985 Free PMC article. Review.
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.
Costabel U, Bendstrup E, Cottin V, Dewint P, Egan JJ, Ferguson J, Groves R, Hellström PM, Kreuter M, Maher TM, Molina-Molina M, Nordlind K, Sarafidis A, Vancheri C. Costabel U, et al. Among authors: kreuter m. Adv Ther. 2014 Apr;31(4):375-91. doi: 10.1007/s12325-014-0112-1. Epub 2014 Mar 18. Adv Ther. 2014. PMID: 24639005 Free PMC article. Review.
Interstitial lung diseases: course report.
Kreuter M, Zeynel S, Mishra DR. Kreuter M, et al. Breathe (Sheff). 2016 Sep;12(3):213-215. doi: 10.1183/20734735.011516. Breathe (Sheff). 2016. PMID: 28210293 Free PMC article.
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.
Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Cottin V. Maher TM, et al. Among authors: kreuter m. BMJ Open Respir Res. 2018 Sep 4;5(1):e000289. doi: 10.1136/bmjresp-2018-000289. eCollection 2018. BMJ Open Respir Res. 2018. PMID: 30233802 Free PMC article.
648 results